Back to Search
Start Over
480P Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation.
- Source :
-
Annals of Oncology . 2023 Supplement 4, Vol. 34, pS1649-S1649. 1p. - Publication Year :
- 2023
- Subjects :
- *EPIDERMAL growth factor receptors
*NON-small-cell lung carcinoma
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 34
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 173758434
- Full Text :
- https://doi.org/10.1016/j.annonc.2023.10.554